Volume 8, Number 2—February 2002
An Outbreak of Rift Valley Fever in Northeastern Kenya, 1997-98
|Characteristic||Total (%) n = 202||Priora infection (% of total) n=31||Susceptibleb n=171||Acutec infection (% of susceptible) n=31|
|Age group (years)|
|<15||40 (20)||2 (5)||38||2 (5)|
|15 to 65||150 (74)||25 (17)||125||28 (22)|
|>65||12 (6)||4 (33)||8||1 (13)|
|Male||103 (51)||16 (16)||87||18 (21)|
|Female||99 (49)||15 (15)||84||13 (15)|
|Rural habitation||161 (80)||25 (16)||136||30 (22)|
|Household >4 persons||74 (37)||10 (14)||64||21 (33)|
aAnti-RVF IgG antibody-positive (no immunoglobulin M [IgM]).
bTotal screened minus those with prior infection.
cAnti-Rift Valley fever virus IgM antibody-positive.
1 Members of the World Health Organization (WHO) Hemorrhagic Fever Task Force, in addition to the listed authors, included Paul Arguin, David Ashford, Julianna Grant, Stuart Nichol, and Brian Plikaytis, Centers for Disease Control and Prevention; Marta Valenciano, European Program for Intervention Epidemiology Training, European Union; James N. Mwanzia, Philip Kangethe, Stephen A. Mileso, and Quinto Maloba, Kenya Ministry of Health; Manuela Dunster, Kenyan Medical Research Institute; Alan Kemp and Koos Coetzer, National Institutes of Virology, Sandringham, South Africa; Jean-Jacques Muyembe, Philip M. Mothoka, Gregory C. Gottlieb, John H. Bierke, and Glyn Davies, WHO, Geneva and African Regional Office; Saade Abdallah, International Federation of the Red Cross and Red Crescent; Elizabeth Nicore and Olivier West, Médècins du Monde; and Christine Grace Adhiambo, Africa Medical Research Foundation.
- Page created: August 01, 2012
- Page last updated: August 01, 2012
- Page last reviewed: August 01, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)